Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Than Window Dressing: Ornskov Seen As Key Asset In AbbVie’s Buyout Of Shire

Executive Summary

The Shire CEO will oversee integration of his company into AbbVie and head a focused rare-disease unit in the new company, but longer-term might be in position to succeed AbbVie CEO Gonzalez. AbbVie may look to Sanofi’s acquisition of Genzyme for a template on how to merge a rare diseases specialty play into big pharma.

Advertisement

Related Content

Shire Collaboration Brings Validation To ArmaGen’s Drug-Delivery Technology

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS056280

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel